跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
[68Ga]FAPI
首页
药物
[68Ga]FAPI
[68Ga]FAPI
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Radioactively labeled ligand for fibroblast activation protein-alpha imaging agent and preparation method therefor
US 12667630 B2
申请人: FIVE ELEVEN PHARMA INC
优先权: 2021
CN
US
WO
4 件公开
FAPI dimer compound, FAPI dimer-based positron emission tomography (PET) imaging agent for tumor diagnosis, and preparation method and use thereof
US 11952368 B2
申请人: UNIV XIAMEN
优先权: 2021
CN
US
2 件公开
FAP INHIBITOR, FAP-TARGETED NUCLIDE PROBE. AND APPLICATION THEREOF
WO 2024222888 A1
申请人: SHANGHAI INST MATERIA MEDICA CAS
优先权: 2023
CN
WO
2 件公开
一种FAP抑制剂和靶向FAP的核素探针及应用
CN 114716505 B
申请人: 首都医科大学附属北京朝阳医院
优先权: 2022
CN
一种靶向FAP及PSMA双靶点抑制剂、分子探针及应用
CN 116082306 B
申请人: 北京肿瘤医院(北京大学肿瘤医院)
优先权: 2023
CN
FAPI tetramer compound, tumor diagnosis PET imaging agent based on FAPI tetramer and preparation method and application of tumor diagnosis PET imaging agent
CN 116514900 A
申请人: THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV XIAMEN FIRST HOSPITAL XIAMEN RED CROSS HOSPITAL XIAMEN
优先权: 2023
CN
METHOD FOR DIAGNOSING OR IMAGING RENAL CELL CARCINOMA USING HETERODIMERIC RADIOACTIVE COMPOUND
WO 2025076679 A1
申请人: YANTAI LANNACHENG BIOTECHNOLOGY CO LTD
优先权: 2023
WO
Application of FAP + myofibroblast as target spot in preparation of medicine or reagent for preventing, diagnosing or treating aortic aneurysm
CN 117653732 A
申请人: ZHONGSHAN HOSPITAL FUDAN UNIV
优先权: 2023
CN
Application of 18F-FAPI-42 in preparation of product for diagnosing lung lymphangioleiomyomatosis
CN 119386215 A
申请人: THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV GUANGZHOU RESPIRATORY CENTER
优先权: 2024
CN
一种镓-68/镥-177/铽-161标记半胱氨酸改性的FAPI配合物及其制备方法和应用
CN 120424052 B
申请人: 上海交通大学
优先权: 2025
CN
第 1 / 2 页
上一页
下一页
药物
反馈